Agilent Agrees to Acquire Resolution Bioscience for $550 Million

Agilent Technologies Inc., a provider of electronic equipment and testing tools to health-care companies, has agreed to acquire Resolution Bioscience to build its diagnostic offerings related to cancer treatment.

Santa Clara, California-based Agilent will pay $550 million in cash and an extra $145 million if Resolution hits certain performance milestones. Resolution develops and commercializes next-generation sequencing, or NGS-based, precision oncology products.

“By adding Resolution Bioscience’s liquid biopsy-based diagnostic technologies to our portfolio, we are strengthening our offering to our biopharma customers,” Agilent President and CEO Mike McMullen said in a statement. “This also accelerates our strategy to broaden access ...